Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LALBA-OA is an oral dietary supplement developed by KTH Biopharma, formulated with a combination of alpha-lactalbumin, oleic acid, and vitamin C. It is marketed for immune support and as supportive care for patients undergoing cancer treatment. The combination of alpha-lactalbumin and oleic acid is known in scientific literature to form complexes (often referred to as HAMLET or BAMLET) that may exhibit selective cytotoxicity against tumor cells by inducing apoptosis. However, LALBA-OA is positioned as a nutritional supplement to bolster the immune system and provide overall health support during recovery rather than as a primary therapeutic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LALBA-OA.